Author:
Hannun Pedro,Felipe Claudia,Ferreira Alexandra,Sandes-Freitas Tainá,Cristelli Marina,Aguiar Wilson,Franco Marcello,Campos Erika,Gerbase de Lima Maria,Tedesco-Silva Hélio,Medina-Pestana José
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Pharmacology (medical),Pharmacology
Reference32 articles.
1. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation;Evenou;J Pharmacol Exp Ther,2009
2. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients;Friman;Am J Transplant,2011
3. Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results;Russ;Am J Transplant,2013
4. Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients;Tedesco-Silva;Am J Transplant,2013
5. Maintenance immunosuppression regimens: conversion, minimization, withdrawal, and avoidance;Yang;Am J Kidney Dis,2006